The following news release describing a study of d
June 10, 2013
Vancouver, British Columbia (June 10, 2013) – Using positron emission tomography (PET) imaging of the brain, researchers have identified a sweet spot that operates in a disorderly way when simple sugars are introduced to people with insulin resistance, a precursor to type 2 diabetes. For those who have the metabolic syndrome, a sugar drink resulted in a lower-than-normal release of the chemical dopamine in a major pleasure center of the brain. This chemical response may be indicative of a deficient reward system, which could potentially be setting the stage for insulin resistance. This research could revolutionize the medical community's understanding of how food-reward signaling contributes to obesity, according to a study being presented at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.
"Insulin resistance is a significant contributor to obesity and diabetes," said Gene-Jack Wang, MD, lead author of the study and professor of radiology at Stony Brook University and researcher at the U.S. Department of Energy's Brookhaven National Laboratory in Upton, N.Y. "A better understanding of the cerebral mechanisms underlying abnormal eating behaviors with insulin resistance would help in the development of interventions to counteract the deterioration caused by overeating and subsequent obesity. We suggest that insulin resistance and its association with less dopamine release in a central brain reward region might promote overeating to compensate for this deficit."
" … an abnormal dopamine response to glucose ingestion … may be the link we have been looking for between insulin resistance and obesity."
— Gene-Jack Wang
An estimated one-third of Americans are obese, according to the U.S. Centers for Disease Control and Prevention. The American Diabetes Association estimates that about 26 million Americans are living with diabetes and another 79 million are thought to be prediabetic, including those with insulin resistance.
The tendency to overeat may be caused by a complex biochemical relationship, as evidenced by preliminary research with rodents. Dr. Wang's research marks the first clinical study of its kind with human subjects.
"Animal studies indicated that increased insulin resistance precedes the lack of control associated with pathological overeating," said Wang. "They also showed that sugar ingestion releases dopamine in brain regions associated with reward. However, the central mechanism that contributes to insulin resistance, pathological eating and weight gain is unknown."
He continued, "In this study we were able to confirm an abnormal dopamine response to glucose ingestion in the nucleus accumbens, where much of the brain's reward circuitry is located. This may be the link we have been looking for between insulin resistance and obesity. To test this, we gave a glucose drink to an insulin-sensitive control group and an insulin-resistant group of individuals and we compared the release of dopamine in the brain reward center using PET."
These images show that insulin-sensitive (normal) subjects had significantly higher dopamine release in the brain's reward regions compared with insulin-resistant subjects when both groups were given a sugary drink prior to the scans. The lower response of the insulin-resistant subjects may play a role in abnormal eating behavior and possibly increase their potential for developing diabetes.
In this study, a total of 19 participants—including 11 healthy controls and eight insulin-resistant subjects—consumed a glucose drink and, on a separate day, an artificially sweetened drink containing sucralose. After each drink, PET imaging with C-11 raclopride—which binds to dopamine receptors—was performed. Researchers mapped lit-up areas of the brain and then gauged striatal dopamine receptor availability (which is inversely related to the amount of natural dopamine present in the brain). These results were matched with an evaluation in which patients were asked to document their eating behavior to assess any abnormal patterns in their day-to-day lives. Results showed agreement in receptor availability between insulin-resistant and healthy controls after ingestion of sucralose. However, after patients drank the sugary glucose, those who were insulin-resistant and had signs of disorderly eating were found to have remarkably lower natural dopamine release in response to glucose ingestion when compared with the insulin-sensitive control subjects.
"This study could help develop interventions, i.e., medication and lifestyle modification, for early-stage insulin-resistant subjects to counteract the deterioration that leads to obesity and/or diabetes," said Wang. "The findings set a path for future clinical studies using molecular imaging methods to assess the link of peripheral hormones with brain neurotransmitter systems and their association with eating behaviors."
Scientific Paper 29: Gene-Jack Wang, Radiology, Stony Brook University, Upton, NY; Jean Logan, Elena Shumay, Joanna Fowler, Bioscience, Brookhaven National Laboratory, Upton, NY; Antonio Convit, Psychiatry, New York University, New York, NY; Tomasi Dardo, Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, Upton, NY; Nora Volkow, National Institute on Drug Abuse, Bethesda, MD, "Peripheral insulin resistance affects brain dopaminergic signaling after glucose ingestion," SNMMI's 60th Annual Meeting, June 8–12, 2013, Vancouver, British Columbia.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI's more than 19,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.
2013-1548 | Media & Communications Office
This is a print-friendly version of this news release. To see the full content, go to: